Cerebral Protection Target institutional buyers performing transcatheter procedures such as TAVR who are seeking full brain embolic protection solutions during periprocedural phases. Position POINT-GUARD as a next generation protection device to reduce stroke risk and improve procedural outcomes.

Early Stage Financing Capitalize on recent venture funding and debt financing to support clinical development and regulatory readiness. Use funding milestones to engage investors, hospital systems, and strategic partners about accelerating trials and potential co-development or procurement opportunities.

Board Expertise Leverage the addition of industry experts on the board to validate clinical relevance and to open advisory channels with leading cardiology and neurology thought leaders. Target speaking engagements, KOL endorsements, and hospital partnerships through these connections.

Clinical Development Highlight the unmet need for full brain protection in structural heart procedures and actively seek early-adopter hospitals to participate in feasibility and pivotal studies. Emphasize potential to differentiate from existing embolic protection approaches.

Market Readiness Identify healthcare systems and medtech distributors with appetite for innovative CEP solutions and provide compelling value propositions around patient safety, procedural efficiency, and potential payer interest. Prepare for regulatory clearance timelines and transition planning once the device advances toward clearance.